PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

darunavir vs glecaprevir/pibrentasvir

Side-by-side comparison of darunavir and glecaprevir/pibrentasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.

moderate Known Drug Interaction

glecaprevir/pibrentasvir ↑ glecaprevir ↑ pibrentasvir Co-administration of darunavir/ritonavir with glecaprevir/pibrentasvir is not recommended.

Recommendation: This combination is not recommended, so you should ask your doctor for a different treatment option.

Drug Class
darunavir HIV Protease Inhibitor
glecaprevir/pibrentasvir NS3/4A/NS5A Inhibitor (HCV)
Type
darunavir Prescription
glecaprevir/pibrentasvir Prescription
Summary
darunavir

Darunavir is a medicine used to treat HIV. It belongs to a class of drugs called protease inhibitors and must be taken with ritonavir.

glecaprevir/pibrentasvir

Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.

What It Treats
darunavir

Darunavir is used to treat HIV-1 infection in adults and children 3 years and older. It must be taken with ritonavir and other HIV medicines. Darunavir helps to lower the amount of HIV in your body.

glecaprevir/pibrentasvir

Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.

How It Works
darunavir

Darunavir is a protease inhibitor. It works by blocking an enzyme called protease that HIV needs to make copies of itself. This helps to slow down the spread of HIV in your body.

glecaprevir/pibrentasvir

Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.

Common Side Effects
darunavir
  • Diarrhea
  • Nausea
  • Rash
  • Headache
  • Abdominal pain
glecaprevir/pibrentasvir
  • Headache
  • Feeling tired
  • Nausea
FAERS Reports
darunavir
  • Baby exposed to drug during pregnancy 1,150
  • Interaction between medicines 981
  • Pain 889
  • Emotional upset 812
  • Worry 811
glecaprevir/pibrentasvir
  • Feeling tired 2,561
  • Headache 2,203
  • Nausea 1,125
  • Itching 653
  • Diarrhea 477
Serious Warnings
darunavir

Darunavir can cause liver problems. Your doctor should check your liver before you start taking darunavir and during treatment. Tell your doctor right away if you have any signs of liver problems, such as yellowing of the skin or eyes.

glecaprevir/pibrentasvir

Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.

Pregnancy
darunavir

Tell your doctor if you are pregnant or plan to become pregnant. The recommended dose during pregnancy is 600 mg twice daily with ritonavir 100mg and food. Women with HIV should not breastfeed because HIV can be passed to the baby through breast milk.

glecaprevir/pibrentasvir

It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.

How to Read This darunavir vs glecaprevir/pibrentasvir Comparison

darunavir is classified in the HIV Protease Inhibitor drug class, while glecaprevir/pibrentasvir sits within the NS3/4A/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.

Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, darunavir has 4,643 submissions while glecaprevir/pibrentasvir has 7,019. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to darunavir increases the amount of glecaprevir and pibrentasvir that stays in your body. this can make the hepatitis c medication more likely to cause side effects.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.

A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between darunavir and glecaprevir/pibrentasvir - always consult your physician or pharmacist first.

Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.